370 related articles for article (PubMed ID: 9818749)
1. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
2. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
3. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
4. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates.
Reichert-Lima F; Lyra L; Pontes L; Moretti ML; Pham CD; Lockhart SR; Schreiber AZ
Mycoses; 2018 Jun; 61(6):360-365. PubMed ID: 29468746
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
7. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
8. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
Moosa MY; Alangaden GJ; Manavathu E; Chandrasekar PH
J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex.
Vaezi A; Fakhim H; Arastehfar A; Shokohi T; Hedayati MT; Khodavaisy S; Rezaei-Matehkolaei A; Badiee P; Hagen F; Lass-Flörl C; Dannaoui E; Meis JF; Badali H
Mycoses; 2018 Feb; 61(2):134-142. PubMed ID: 29064123
[TBL] [Abstract][Full Text] [Related]
11. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.
Meletiadis J; Antachopoulos C; Stergiopoulou T; Pournaras S; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3329-37. PubMed ID: 17576838
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.
Elefanti A; Mouton JW; Verweij PE; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2014; 58(4):2356-62. PubMed ID: 24514094
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.
Johnson EM; Oakley KL; Radford SA; Moore CB; Warn P; Warnock DW; Denning DW
J Antimicrob Chemother; 2000 Jan; 45(1):85-93. PubMed ID: 10629017
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of Aspergillus species isolated from invasive oral infection in neutropenic patients with hematologic malignancies.
Myoken Y; Sugata T; Myoken Y; Kyo T; Fujihara M; Mikami Y
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999 Feb; 87(2):174-9. PubMed ID: 10052372
[TBL] [Abstract][Full Text] [Related]
15. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
Mortensen KL; Johansen HK; Fuursted K; Knudsen JD; Gahrn-Hansen B; Jensen RH; Howard SJ; Arendrup MC
Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
[TBL] [Abstract][Full Text] [Related]
16. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
J Antimicrob Chemother; 1999 Oct; 44(4):553-5. PubMed ID: 10588320
[TBL] [Abstract][Full Text] [Related]
17. In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone.
Manavathu EK; Dimmock JR; Vashishtha SC; Cutright J; Chandrasekar PH
J Antimicrob Chemother; 1998 Nov; 42(5):585-90. PubMed ID: 9848441
[TBL] [Abstract][Full Text] [Related]
18. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
19. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]